Ligand to Report Third Quarter Results on November 9

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report third quarter 2010 financial results on Tuesday, November 9, 2010. Ligand’s President and CEO, John L. Higgins and Vice President of Finance and CFO, John Sharp will host the conference call.

Third Quarter Earnings Call

 
What: Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.
 
When: Tuesday, November 9, 2010
 
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
 
Webcast:

Conference call and replay accessible at www.ligand.com.

 
Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
 
Replay: (877) 660-6853, Account #: 361 passcode: 359601 (201) 612-7415 outside the U.S.
 

About Ligand Pharmaceuticals

Ligand discovers and develops novel drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, tissue-specific receptor ligand interactions and gene-expression tools. Among its peers, we believe Ligand has assembled one of the largest portfolio of assets including commercial therapies developed in partnership with pharmaceutical companies. Ligand has alliances with the world's leading pharmaceutical companies including GlaxoSmithKline (GSK), Merck, Pfizer, Roche, Bristol-Myers Squibb and AstraZeneca, and has more than 30 programs in various stages of development.



CONTACT:

Ligand Pharmaceuticals Incorporated
John L. Higgins, President and CEO or
Erika Luib, Investor Relations
(858) 550-7896
or
Lippert/Heilshorn & Associates
Don Markley
[email protected]
(310) 691-7100

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.